+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID06272214

Phase II Study of Adjuvant Radiotherapy After Neoadjuvant Chemotherapy and Immunotherapy in Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Led by Zhejiang Cancer Hospital · Updated on 2024-07-16

146

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the role of additional radiotherapy after surgery in patients with esophageal squamous cell carcinoma who have a high risk of cancer returning. This study focuses on those who received chemotherapy combined with immunotherapy before surgery but did not have a complete response in the removed tissue. It is a randomized phase II trial comparing outcomes with and without adjuvant radiotherapy to better understand if this extra treatment improves disease control and survival. Participants are randomly assigned to one of two groups one receives standard treatment including surgery, chemotherapy, immunotherapy, and maintenance immunotherapy for up to one year, while the other group receives the same treatment plus adjuvant radiotherapy starting 4 to 6 weeks after surgery. The radiotherapy is given as intensity-modulated radiation therapy IMRT with a total dose of 45 Gy delivered in 25 sessions over five weeks. After radiotherapy, patients continue immunotherapy maintenance for up to one year or until disease progression. Follow-up visits occur regularly for up to five years. During the study, participants undergo regular assessments including survival tracking, recurrence monitoring, and quality of life evaluations at various timepoints. Researchers will also study biomarkers such as PD-L1 levels and immune cell activity to predict treatment responses and side effects. Safety is closely monitored during radiotherapy and immunotherapy. The primary goal is to measure disease-free survival at two years, with secondary measures including overall survival and recurrence patterns.

CONDITIONS

Brief Title

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

Research Team

Y

YANG YANG, M.D.

W

Weizhen Xu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here